How Long a Bridging Glucocorticoid Should Run in Early Rheumatoid Arthritis
A bridging steroid meant to last three months is heading into its fourth, and stepping on the taper faster than his joints tolerate carries its own real cost for a man whose independence is already more fragile than it looks on paper.
Ted M., a 74-year-old man, lost his wife of forty-six years eight months ago and has spent much of the time since learning, by himself, tasks she used to handle without either of them thinking about it. His rheumatoid arthritis was diagnosed four months ago, and his rheumatologist started him that week on methotrexate alongside a prednisone bridge at 15mg, planned to taper down and off over roughly three months while the methotrexate took full effect. That taper has stalled: every time the dose reaches 7.5mg, his joint symptoms flare noticeably within days, and four months in, he is still taking 7.5mg daily rather than the zero the original plan intended.
EULAR's 2025 update is direct about the intended role of a bridging glucocorticoid: it should be tapered and discontinued as rapidly as clinically feasible, existing to cover the gap while a slower-acting DMARD takes hold, not to substitute for one long-term. A taper that keeps failing at the same dose is, by that logic, a sign his methotrexate hasn't yet done its job, not a reason to simply accept ongoing steroid exposure. But the calculus around continued low-dose steroid in a patient his age isn't uniformly negative either: the GLORIA trial, a genuine randomized trial testing 5mg of prednisolone added to usual care specifically in older RA patients, found real, measurable disease-control benefit over a two-year follow-up in patients recruited specifically for being 65 or older, with the expected rise in glucocorticoid-related adverse events running mostly non-severe rather than the kind that would derail an independent life on their own. What that trial doesn't specifically address is a man eight months into losing his wife of forty-six years, living by himself for the first time in his adult life, whose bone density has not yet even been formally checked, for whom a single hospitalization or a hip fracture would cost him something the guideline's general population estimate doesn't capture.
What a stalled taper is actually telling you
I'd rather escalate his methotrexate dose now than keep him on 7.5mg of prednisone indefinitely. EULAR is explicit that a bridging glucocorticoid should be tapered and discontinued as rapidly as clinically feasible — it's meant to cover the gap while the DMARD takes hold, not to become the actual long-term plan. A taper that keeps failing at the same dose four months in tells me his methotrexate hasn't caught up yet, which is a reason to push the DMARD harder, not to accept the steroid as settled.
I agree with escalating the methotrexate — that part isn't in dispute. Where I'd push back is on treating the current 7.5mg as something to force off him on the original timeline regardless of what happens next. He lost his wife eight months ago and is living alone for the first time in his adult life; a hospitalization or a fracture right now would cost him something a general taper guideline doesn't measure.
The GLORIA trial is real, direct evidence here, not just a sympathetic argument: it randomized older RA patients to 5mg of prednisolone added to usual care and found genuine disease benefit, with the expected rise in steroid-related adverse events running mostly non-severe. That's a different population than 'bridging while waiting on methotrexate,' but it says something concrete about the actual risk of sustained low-dose steroid in a patient his age — it isn't automatically the hazard a strict reading of the bridging guideline implies.
So: escalate methotrexate now, yes. But I'd let him stay at 7.5mg a bit longer on purpose while that has time to work, rather than forcing a taper that's already failed twice at the same dose.
Agreed: methotrexate increased to 20mg weekly, with the prednisone taper explicitly paused at 7.5mg rather than pushed on the original three-month timeline, and a formal re-attempt at tapering once the increased methotrexate dose has had time to work.
Not agreed: how much weight his social circumstances should carry against the general guideline recommendation to taper as rapidly as feasible. The rheumatologist's position is that escalating methotrexate is the actual fix and the steroid pause is a temporary accommodation; the geriatrician's position is that GLORIA's data genuinely complicates how urgently that taper needs to finish in a patient his age and circumstance, not just how comfortable he feels about it.